t2 biosystems - TTOO

TTOO

Close Chg Chg %
0.01 -0.01 -50.00%

Closed Market

0.01

-0.01 (50.00%)

Volume: 32.76K

Last Updated:

Dec 31, 2025, 3:42 PM EDT

Company Overview: t2 biosystems - TTOO

TTOO Key Data

Open

$0.00

Day Range

0.00 - 0.01

52 Week Range

0.00 - 0.43

Market Cap

$280.50K

Shares Outstanding

28.05M

Public Float

15.86M

Beta

0.74

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$6.41

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

122.72K

 

TTOO Performance

1 Week
 
-54.55%
 
1 Month
 
-54.55%
 
3 Months
 
-54.55%
 
1 Year
 
-98.81%
 
5 Years
 
-100.00%
 

TTOO Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About t2 biosystems - TTOO

T2 Biosystems, Inc. is a vitro diagnostics company, which engages in the development of detection of sepsis-causing pathogens. It offers T2Dx instrument, T2Bacteria, T2Candida, T2Biothreat panels, and T2MR technology. The company was founded by Michael J. Cima, Robert S. Langer Jr., Tyler Jacks, Lee Josephson, W. David Lee, and Ralph Weissleder on April 27, 2006 and is headquartered in Lexington, MA.

TTOO At a Glance

T2 Biosystems, Inc.
101 Hartwell Avenue
Lexington, Massachusetts 02421
Phone 1-781-761-4646 Revenue 7.19M
Industry Medical Specialties Net Income -50,077,000.00
Sector Health Technology Employees 113
Fiscal Year-end 12 / 2024
View SEC Filings

TTOO Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 2.277
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -1.084
Enterprise Value to Sales 6.977
Total Debt to Enterprise Value 0.986

TTOO Efficiency

Revenue/Employee 63,654.867
Income Per Employee -443,159.292
Receivables Turnover 5.065
Total Asset Turnover 0.208

TTOO Liquidity

Current Ratio 0.447
Quick Ratio 0.361
Cash Ratio 0.279

TTOO Profitability

Gross Margin -122.744
Operating Margin -655.54
Pretax Margin -696.191
Net Margin -696.191
Return on Assets -144.89
Return on Equity N/A
Return on Total Capital -233.329
Return on Invested Capital N/A

TTOO Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital 230.631
Total Debt to Total Assets 142.248
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital 30.743
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for T2 Biosystems - TTOO

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
18.13M 28.06M 22.30M 7.19M
Sales Growth
+117.52% +54.76% -20.50% -67.75%
Cost of Goods Sold (COGS) incl D&A
20.64M 20.70M 20.95M 16.02M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
3.16M 2.54M 2.27M 859.00K
Depreciation
3.16M 2.54M 2.27M 859.00K
Amortization of Intangibles
- - - -
-
COGS Growth
+23.15% +0.29% +1.19% -23.52%
Gross Income
(2.51M) 7.36M 1.35M (8.83M)
Gross Income Growth
+70.17% +392.56% -81.58% -751.59%
Gross Profit Margin
-13.87% +26.21% +6.07% -122.74%
2020 2021 2022 2023 5-year trend
SG&A Expense
37.68M 50.33M 55.40M 38.32M
Research & Development
16.92M 21.80M 25.77M 13.49M
Other SG&A
20.76M 28.53M 29.63M 24.83M
SGA Growth
-13.63% +33.56% +10.08% -30.82%
Other Operating Expense
- - - -
-
Unusual Expense
(256.00K) 1.01M 1.91M (2.91M)
EBIT after Unusual Expense
(39.94M) (43.98M) (55.96M) (44.24M)
Non Operating Income/Expense
76.00K 318.00K 39.00K (495.00K)
Non-Operating Interest Income
- 14.00K 112.00K 8.00K
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
6.93M 5.58M 6.08M 5.34M
Interest Expense Growth
-1.87% -19.57% +9.11% -12.18%
Gross Interest Expense
6.93M 5.58M 6.08M 5.34M
Interest Capitalized
- - - -
-
Pretax Income
(46.80M) (49.24M) (62.00M) (50.08M)
Pretax Income Growth
+20.69% -5.22% -25.92% +19.23%
Pretax Margin
-258.12% -175.50% -277.98% -696.19%
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(46.80M) (49.24M) (62.00M) (50.08M)
Minority Interest Expense
- - - -
-
Net Income
(46.80M) (49.24M) (62.00M) (50.08M)
Net Income Growth
+20.69% -5.22% -25.92% +19.23%
Net Margin Growth
-258.12% -175.50% -277.98% -696.19%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(46.80M) (49.24M) (62.00M) (50.08M)
Preferred Dividends
- - - 330.00K
-
Net Income Available to Common
(46.80M) (49.24M) (62.33M) (50.08M)
EPS (Basic)
-1928.5 -1549.8 -1222.121 -19.1867
EPS (Basic) Growth
+70.25% +19.64% +21.14% +98.43%
Basic Shares Outstanding
24.27K 31.77K 51.00K 2.61M
EPS (Diluted)
-1928.5 -1549.8 -1222.121 -19.1867
EPS (Diluted) Growth
+70.25% +19.64% +21.14% +98.43%
Diluted Shares Outstanding
24.27K 31.77K 51.00K 2.61M
EBITDA
(37.04M) (40.44M) (51.77M) (46.29M)
EBITDA Growth
+23.49% -9.16% -28.04% +10.58%
EBITDA Margin
-204.31% -144.11% -232.12% -643.60%

T2 Biosystems in the News